Observes safety and effects of deucravacitinib in Korean adults with plaque psoriasis
Studies how deucravacitinib works and is tolerated in Korean adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Key facts
- Where
- Seoul, South KoreaSee the 2 sites
Where in South Korea
- Novotech Laboratory Korea Co., Ltd.Seoul, South KoreaTaking people
- SeoulSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06258668
- Record updated
- 6 November 2024
- Original description
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.Read full original descriptionShow less
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Inclusion: Adult participants ≥19 years of age; Diagnosis of moderate-to-severe plaque psoriasis; Candidate for phototherapy or systemic therapy; Will begin deucravacitinib according to approved product label.
Exclusion: Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS); Participants prescribed deucravacitinib for therapeutic indications not approved in Korea.